Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333732 | 1.00 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2333731 | 1.00 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL15198324 | 1.00 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2515174 | 1.00 | NR1H2 (0.44) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2930651 | 0.90 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL2930654 | 0.90 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL1052491 | 0.90 | NR1H2 (0.50) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL1220866 | 0.88 | ALDH1A1 (0.45) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL1219339 | 0.88 | ALDH1A1 (0.45) | NR1H2MEN1ALDH1A1KMT2ATSHR | |
| SCHEMBL21682484 | 0.88 | ALDH1A1 (0.45) | NR1H2MEN1ALDH1A1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| EP-4688792-A1 | KRAS INHIBITORS | Eli Lilly and Company (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| WO-2024206766-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY (US) | 2024-10-03 | — | — | WO | disclosed |
| WO-2014065413-A1 | TRIAZOLE-ISOXAZOLE COMPOUND AND MEDICAL USE THEREOF | 日本たばこ産業株式会社 (JP) | 2014-05-01 | — | — | WO | disclosed |
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-12-31 | — | — | US | disclosed |
| CN-101495186-A | Inhibitors of undecaprenyl pyrophosphate synthase | NOVARTIS AG (CH) | 2009-07-29 | — | — | CN | disclosed |
| EP-2059305-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | Novartis Ag (CH) | 2009-05-20 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2008014307-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325948-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | NR1H2 1323/4885MEN1 2345/4885ALDH1A1 3119/4885 |
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | NR1H2 531/4885MEN1 2302/4885ALDH1A1 135/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1327/4885MEN1 270/4885ALDH1A1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.